aTYR PHARMA (ATYR) EPS (Basic) (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly EPS (Basic) came in at -$0.11 in Q2 2026, up 50.81% on a YoY basis from -$0.07 in Q2 2025, and up 5.41% quarter-over-quarter from -$0.12 in Q1 2026.
Powered by 
Analysis
aTYR PHARMA (ATYR) EPS (Basic) (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has reported EPS (Basic) for 13 consecutive years, with -$0.11 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EPS (Basic) rose 50.81% year-over-year to -$0.11; the trailing twelve-month figure through Jun 2026 stood at -$0.65 (up 16.19% YoY), and the FY2025 full-year result was -$0.83, up 8.71% from the prior year.
- EPS (Basic) advanced to -$0.11 in Q2 2026 per ATYR's latest filing, from -$0.12 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$0.11 in Q2 2026 and bottomed at -$0.47 in Q3 2022.
- Historically, EPS (Basic) has averaged -$0.26 across 5 years, with a median of -$0.24 in 2023.
- The sharpest annual moves came in 2023 and 2025: EPS (Basic) surged 53.21% in 2023, then declined 15.01% in 2025.
- Over 5 years, EPS (Basic) stood at -$0.28 in 2022, then dropped by 6.42% to -$0.3 in 2023, then gained by 28.44% to -$0.21 in 2024, then rose by 25.31% to -$0.16 in 2025, then surged by 30.29% to -$0.11 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$0.11, -$0.12, and -$0.16 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 12.62 |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -1.96 |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 7.70 |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -0.40 |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | -0.11 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.11 |
| Mar 31, 2026 | -0.12 |
| Dec 31, 2025 | -0.16 |
| Sep 30, 2025 | -0.28 |
| Jun 30, 2025 | -0.23 |
| Mar 31, 2025 | -0.18 |
| Dec 31, 2024 | -0.21 |
| Sep 30, 2024 | -0.24 |
| Jun 30, 2024 | -0.24 |
| Mar 31, 2024 | -0.25 |
| Dec 31, 2023 | -0.30 |
| Sep 30, 2023 | -0.22 |
| Jun 30, 2023 | -0.25 |
| Mar 31, 2023 | -0.30 |
| Dec 31, 2022 | -0.28 |
| Sep 30, 2022 | -0.47 |
| Jun 30, 2022 | -0.45 |
| Mar 31, 2022 | -0.46 |
| Dec 31, 2021 | -0.46 |
| Sep 30, 2021 | -0.43 |